Randomized phase II trial of hypofractionated proton versus carbon ion radiation therapy in patients with sacrococcygeal chordoma-the ISAC trial protocol by Matthias Uhl et al.
Uhl et al. Radiation Oncology 2014, 9:100
http://www.ro-journal.com/content/9/1/100STUDY PROTOCOL Open AccessRandomized phase II trial of hypofractionated
proton versus carbon ion radiation therapy in
patients with sacrococcygeal chordoma-the ISAC
trial protocol
Matthias Uhl1,2*, Lutz Edler3, Alexandra D Jensen1,2, Gregor Habl1, Jan Oelmann1, Falk Röder1, Oliver Jäckel2,3,
Jürgen Debus1,2,3 and Klaus Herfarth1,2Abstract
Background: Chordomas are relatively rare lesions of the bones. About 30% occur in the sacrococcygeal region.
Surgical resection is still the standard treatment. Due to the size, proximity to neurovascular structures and the
complex anatomy of the pelvis, a complete resection with adequate safety margin is difficult to perform. A radical
resection with safety margins often leads to the loss of bladder and rectal function as well as motoric/sensoric
dysfunction. The recurrence rate after surgery alone is comparatively high, such that adjuvant radiation therapy is
very important for improving local control rates. Proton therapy is still the international standard in the treatment of
chordomas. High-LET beams such as carbon ions theoretically offer biologic advantages in slow-growing tumors.
Data of a Japanese study of patients with unresectable sacral chordoma showed comparable high control rates
after hypofractionated carbon ion therapy only.
Methods and design: This clinical study is a prospective randomized, monocentric phase II trial. Patients with
histologically confirmed sacrococcygeal chordoma will be randomized to either proton or carbon ion radiation
therapy stratified regarding the clinical target volume. Target volume delineation will be carried out based on CT
and MRI data. In each arm the PTV will receive 64 GyE in 16 fractions. The primary objective of this trial is safety and
feasibility of hypofractionated irradiation in patients with sacrococygeal chordoma using protons or carbon ions in
raster scan technique for primary or additive treatment after R2 resection. The evaluation is therefore based on the
proportion of treatments without Grade 3–5 toxicity (CTCAE, version 4.0) up to 12 months after treatment and/or
discontinuation of the treatment for any reason as primary endpoint. Local-progression free survival, overall survival
and quality of life will be analyzed as secondary end points.
Discussion: The aim of this study is to confirm the toxicity results of the Japanese data in raster scan technique
and to compare it with the toxicity analysis of proton therapy given in the same fractionation. Using this data, a
further randomized phase III trial is planned, comparing hypofractionated proton and carbon ion irradiation.
Trial registration: ClinicalTrials.gov Identifier: NCT01811394.
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The advantage of radiation therapy with particles is based
on the particular physical and biological characteristics of
ions. Protons and carbon ions as compared to photons
lead to an improved conformal dose distribution, which
allows a better sparing of surrounding tissue and
concurrent dose escalation in the tumor. Carbon ions
seem to have an additional biological advantage due
to their higher biological effectiveness in contrast to
protons [1-3]. Complex double-strand breaks of the
DNA seem to be the reason [4,5]. Therefore, heavy
ions provide a promising treatment option for tumors
with lower radiosensitivity and critical location. Increased
cure rates and low toxicity of a particle therapy are the
expected results in tumors with low alpha/beta values.
Chordomas, as a typical example, are rare malignant
tumors (1-4% of all malignant bone tumors). This slow
growing tumor arises from embryonic remnants of the
chorda dorsalis. The incidence rate is 0.1/1,000,000 [6].
Historically, a higher incidence of sacral chordomas
than skull base chordomas was assumed [7]. However,
published SEER data of 400 patients with chordoma
show an equal distribution with 32% on the skull base,
32.8% spinal and 29.2% in the sacral region [6]. The
histological classification is divided into three types:
conventional (most common type), chondroid and
dedifferentiated [7-9]. The quality of surgical margin is
the most important factor for local control and survival
[10-12]. An adequate safety margin can only be achieved
in about 50% of the patients with sacrococcygeal
chordomas [11-13]. Therefore, after R1/R2 resection
the local recurrence rate is about 100% without any
additional therapy. Fuchs et al. could show a significantly
different time of local control between patients with
radical resection and subtotal resection [11]. Nevertheless
the data of Park et al. indicate a large difference in local
failure rate between patients irradiated for primary versus
recurrent sacral chordomas after surgery. Hence, an
adjuvant high-dose radiotherapy for acceptable control
rates is required after complete resection [14]. High
conformal techniques help to achieve a safe dose
escalation. As mentioned above, due to their physical
properties ions provide the best conditions. Proton
therapy is the current international standard in irradiation
of skull base chordomas. The results of the Loma Linda
University Medical Centre, the Massachusetts General
Hospital in Boston, and the PSI in Villingen (Switzerland)
show excellent control rates for proton therapy [15-17]. In
the GSI in Darmstadt, we irradiated with carbon ions
by now about 300 patients with skull base chordoma/
chondrosarcoma. Published data of the first 96 patients
that were treated at the GSI displayed 3- and 5-year local
tumor control rates (LC) of 81% and 70% with overall
survival (OS) rates of 92% and 89%, respectively [18].Currently, there is a randomized phase III trial under
recruitment, testing protons against heavy ions in patients
with skull base chordoma in our department [19]. In
addition, over 70 patients with sacral chordoma were
treated with carbon ion in our heavy ion therapy
center (HIT) between 2010 and 2012. Furthermore, in
chordomas of the sacral region surgical resection is
still the standard therapy and the extent of surgical
resection is important for the local disease free inter-
val [11]. Due to the size, proximity to neurovascular
structures and the complex anatomy of the pelvis a
complete resection with adequate safety margin is
often difficult to realize. A radical resection, especially
above S2, often leads to urinary and bowel incontin-
ence as well as motoric/sensoric dysfunctions [20,21].
An adjuvant/additive treatment with charged parti-
cles can increase the local control rate after surgery
[14,22,23]. Radiobiological considerations lead to low
alpha/beta value for chordoma (the tissue-specific
constant that indicates the sensitivity of the tissue for
the probability of late toxicity by increasing the single
dose). The alpha/beta value for chordoma cells (2 Gy)
[24] is significantly lower for other organs at risk
(bladder alpha/beta 4.0 Gy; rectum alpha/beta
3.9 Gy). Thereby, a higher single dose can be used,
treating the chordoma cells more effectively without
increasing the risk of side effects. A Japanese trial
with primary carbon ions irradiation without previous
surgery confirmed this radiobiological model [25].
The data show an excellent control rate after primary
radiotherapy with carbon ions in patients with inoper-
able sacral chordoma. 95 patients were treated with 16
fractions carbon ions over 4 weeks with a total dose of
52.8 GyE up to 73.6 GyE (70.4 Gy median TD). The
fraction dose therefore was 3.3 GyE up to 4.6 GyE
(4.4 Gy median SD) applied four times a week. At 5 years,
the OS rate and LC rate were 86% and 88%, respectively.
The rate of acute/late skin toxicity grade 3 and higher was
6.3%. Only one patient (1%) showed transient rectal
bleeding 20 months after therapy (Grade II). The pub-
lished study with ion irradiation of sacral chordoma was
conducted using a passive beam modulation. A further
development of the ion irradiation is the active beam
delivery using raster-scanning method. The advantage of
this method is especially the lower neutron production
when used in our department. As a result of the higher
neutron production the passive beam modulation shows
no advantage over IMRT regarding secondary cancer risk
[26]. Until now there have been no published data of
hypofractionated irradiation with protons in sacral chor-
doma. Therefore, this is the first randomized Phase II trial
protocol with hypofractionated carbon ion versus proton
treatment in patients with sacrococcygeal chordoma in a
single institution open for recruitment since January 2013.
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Primary objectives/endpoints of this study
The primary objective of this trial is the evaluation of
safety and feasibility of hypofractionated irradiation
in patients with sacrococygeal chordoma using ions
(protons or carbon ions) in raster scan technique for
primary or additive treatment after R2 resection. The
evaluation is based on as primary endpoint defined
as the proportion of patients treated without Grade
3–5 toxicity (NCI-CTC-AE) up to 12 months after treat-
ment and/or without discontinuation of the treatment
for any reason.
Secondary objectives
Assessment of local progression free survival (LPFS) is
determined from start of treatment until local progression
in imaging (>10% size increase). Further objectives
are overall survival (OS) from start of treatment until
death or censoring and Quality of life (QoL) using
the EORTC-QLQ30 questionnaire.
Study design
The study is a parallel group prospective clinical
phase II trial of patients with sacrococcygeal chordoma,
randomized to one of the two treatment arms (arm A:
proton therapy, arm B: carbon ion therapy). A total dose
of 64 GyE in 16 fractions to the PTV (see target definition
below) will be given in arm A using protons and in arm B
using carbon ions. The accrual period of this trial will
take approximately two years with a follow up time
of 12 months for each patient. Patients matching theFigure 1 Workflow.eligibility criteria and willing to participate with informed
consent are registered (Figure 1).
Inclusion criteria
Histological confirmation of sacrococcygeal chordoma.
Karnofsky performance status ≥ 70%.





Lack of macroscopic tumor.
Tumor extension in craniocaudal direction >16 cm due
to technical limitation.
Metal implants at the level of the tumor that could
influence the treatment planning.
Inability of the patient to lie quiet for at least
20 minutes (e.g. due to pain).
Prior radiotherapy of the pelvic region.
Simultaneous participation in another trial that could
influence the results of the study.
Active medical implants without treatment approval at the
time of ion irradiation (e.g., cardiac pacemaker, defibrillator).
Randomization
Randomization will be performed regarding treatment
arms A (protons) and B (carbon ions) stratified by the
volume of CTV (>or ≤ 1 L).
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Examinations for treatment planning consist of a CT
scan (3 mm slice thickness) in treatment position and a
MRI for 3D image correlation. The delineation of the
chordoma requires a T1 weighted post gadolinium and
T2 stir MRI.
Target volume
Gross Tumor Volume (GTV) includes the gross tumor
based on CT and MRI imaging. The Clinical Target
Volume (CTV) is defined as GTV plus surrounding areas
at risk for containing microscopic disease. The CTV
includes the GTV and, after partial resection, the tumour
bed and surgical access path with a margin of 2 cm in
bone and soft tissue. The CTV margins may be smaller if
the GTV is adjacent to the critical normal organs like
small bowel or rectum. The Planning Target Volume
(PTV) includes the CTV with an additional margin of
5 mm in anterior-posterior direction and 7 mm in lateral
direction to compensate set-up variability. The overlap of
PTV and rectum is defined as PTV-Rectum.
Proton/carbon ion therapy
Treatment planning is realized using a treatment planning
system (TPS Siemens) that enables conventional and
biological optimization. After inverse planning proton and
carbon ion treatment is given in active beam application
(raster scanning method).Figure 2 Dose distribution and DVH of a patient treated with 64GyE
dose volume histogram (DVH) of a patient within the trial.Dose prescription
95% of the PTV should obtain the dose of 64 GyE in 16
fractions (5–6 fractions per week). The equivalent
photon dose in 2 Gy/fraction (ED2) is 96 Gy, calculated
for 2 Gy single dose (SD) and α/β value of 2.
Critical normal structure constraints
Rectum, bladder and bowel are defined as organs at risk.
Rectum is defined therefore ranging from the anus to
the recto sigmoid junction, the bowel as the remaining
intestine in the pelvis without rectum. The maximum
dose to the PTV-rectum is 57.6 GyE (90% isodose). The
ED2 (2 Gy SD, α/β = 3.9 Gy) is 73.2 Gy. One third of
the circumference should be below the 35% isodose
(ED2: 20 Gy). The maximum dose for the other parts of
the intestine is 51.2 GyE (80% isodose, ED2: 61.4 Gy). This
dose may only appear in a small volume. The QUANTEC
criteria for the rectum and the other parts of the intestine
have to be observed (V50 < 50%, V60 < 35%, V65 < 25%,
V70 < 20% and V75 < 15%) (Figure 2). The maximum dose
to the cauda equina is 60 Gy (ED2).
Assessment of efficacy parameters
Toxicity and safety
To evaluate the toxicity, this study will use the
International Common Terminology Criteria for Adverse
Events (CTCAE) version 4.0 for toxicity and adverse event
reporting. Safety and toxicity of the study treatment willcarbon ion therapy within the ISAC trial. a) dose distribution and b)
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studies (MRI or CT). At enrollment, each patient will be
asked for his medical history and pass through a basic
clinical examination with regard to already existing
problems. During radiation therapy the patient is monitored
continuously. Once a week, a meeting with the investigator
will take place in order to record the adverse effects. At the
end of the treatment and in the follow up visits the clinical
symptoms and toxicity will be documented again.
Follow up visits are planned for 6–8 weeks, 4 months,
8 months and 12 months after irradiation. A safe
feasibility exists, if no grade 3 or higher toxicity has
occurred (including toxicity-related death, Grade 5)
from start of radiation until 12 months after the end of
therapy, and if the therapy was not canceled due to any
toxicity (grade 1–4). It will be evaluated be the respective
portion of patients denoted SFR (safe feasibility rate).
Quality of life
The quality of life (QoL) is detected using the EORTC
QLQ-C30 questionnaires that are filled in by the patient
before treatment, at the end of treatment and 12 months
after irradiation. The evaluation of the questionnaires is
carried out for the individual patients after the complete
collection of all data. To determine a change in QoL it
will be compared with the pretherapeutic QoL for each
patient in both arms. QoL will be compared between the
two arms of the study after end of radiation and at end
of study for the patients. For the analysis of the EORTC
questionnaires the EORTC QLQ-C30 Scoring Manual
will be used.
Local progression free survival (LPFS)
The effectiveness of treatment is examined through MRI
follow-ups. A progressive disease (PD) is achieved if the
tumor size increases 10% or more, measured as the
longest dimension in cranial-caudal, anterior-posterior
and lateral direction. This definition of PD is based on
the observation of a temporary tumor swelling after the
particle therapy. A new tumor nodule and a tumor
growth >10% in one direction (for example toward the
gluteal muscles) will also be evaluated as PD. Since
chordomas usually have a very low proliferation rate
(Ki 67: <5%), an assessment by RECIST criteria is too
insensitive for detecting a PD.
Overall survival (OS)
Overall survival is a secondary endpoint of the study.
The duration of survival is the time interval between
beginning of radiotherapy and the date of death due to
any cause or to loss to follow-up (censored observation).
Patients not reported dead or lost to follow-up will be
censored at the date of the last follow-up examination
(Figure 3).Statistical consideration and analysis
With the present study, basic data are obtained for
hypofractionated carbon ion radiation and proton
radiation in sacral chordoma patients to be used for
planning a confirmative randomized phase III trial
comparing proton and carbon ion irradiation. At present,
hypofractionated carbon ion radiation is considered as the
standard, supported by data already existing in Japan.
However, the treatment in Japan was performed without
using the raster-scanning method. Nevertheless, these
data can serve as historical control for the planning of this
pilot study and provide the framework for the assessment
of safety and feasibility of the proposed study treatments
using the SFR as endpoint. Each of the planned study
treatments (Arm A: protons or arm B: carbon ions) will
be tested separately for this endpoint in a non-inferiority
study design in comparison with that (historical) control.
The comparative evaluation of favorable toxicity is
assessed in an exploratory comparison by comparing
the SFR of both arms. With these results, a further trial is
then planned to evaluate the efficacy and safety of hypo-
fractionated irradiation with carbon ions or protons with
active beam delivery of sacral chordoma. Consequently, the
following two questions will be considered in preparation
for the subsequent confirmatory study:
a) Is the toxicity of carbon ion irradiation (Arm B)
non-inferior to the current standard?
b) Is the toxicity of the proton irradiation (arm A)
non-inferior to the current standard?
The number of patients to be recruited is calculated
separately for each arm with an assumed standard
toxicity rate of 7% (Grade 3–5 NCI-CTC AE Tox,
including premature termination). Thus, the safety rate
is set to 93% accounting for the Japanese results, where
a toxicity of grade 3 or higher in 6.3% of patients was
found [25]. Identical non-inferiority limits for toxicity
and statistical error probabilities (type I error = type II
error = 10%) are selected for each of the two arms.
Randomization is used to obtain a balanced patient
population in both groups and based on permuted block
randomization stratified for the CTV size (> or ≤ 1 L).
Comparison between the two arms will be carried out as
a secondary comparison. The non-inferiority of each of
the two arms compared to the standard is assessed in a
one-sided hypothesis test: H0: SDR <93% versus H1:
SDR > = 93% - DELTA. For the proposed pilot trial a
non-inferiority limit (DELTA) of 13% is assumed. To test
the efficacy and safety of the treatment, 45 evaluable
patients per arm are required to reach a power of
90% (type II error = 10%) at a significance level 10%
(type I error). Non-inferiority is denied, if safe feasibility is
possible in less than 40 patients (i.e. if more than 5 of the
Figure 3 Examinations during the trial in tabular view. RT = radiothrapy.
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tests is to be tested with a power of 90% (power = 90%,
beta = 0.1) in a one-sample binomial test. Confidence
intervals of the SFR are calculated as describing
parameters. With an estimated drop out rate of
approximately 10%, 50 patients should be included in
each arm in order to obtain 45 evaluable patients. This
sample size calculation is based on the PASS software
of 2005 and the method of Blackwelder (1982) for
non-inferiority trials [27]. The secondary endpoints
OS and LPFS will be analyzed via descriptive methods
of censored survival times (Kaplan Meier method).
Regular study end
The estimated accrual period is 24 months. The regular
end of the treatment period for each patient is three weeks
after initiation of radiation therapy (after 16 fractions).
The regular end of study participation for each patient is
after a follow up period of 12 months.
Prematurely study termination
Reasons for premature termination of the entire study
are unacceptable risks and toxicities as specified by the
Safety Board as occurrence of a toxicity of grade 5, of 2
consecutive grade 4 toxicities or 5 consecutive grade 3
toxicities judged to be definitively associated with study
therapy. Other reasons are new scientific findings during
the period of study that require a different treatment.
Individual reasons for premature study termination are
serious events or a patient’s request.
Data safety monitoring board (DSMB)
An independent Data and Safety Monitoring Board
(DSMB) will monitor the recruitment, the reported
adverse events and the data quality. Based on its review
the DSMB will provide the Principal Investigator (PI)
with recommendations regarding trial modification,
continuation or termination.Data collection and management
All patient related data are collected pseudonymously. An
individual patient number characterizes each patient. The
data collection is based on case report forms (documenta-
tion forms/case report forms). The originals of all docu-
ments are kept in the study center. According to the §13 of
the German GCP-Regulation, all important trial documents
will be archived for at least 15 years after the end of the
ISAC trial. According to the §28c of the German X-Ray
Regulation (RöV) and the §87 of the German Radiation
Protection Regulation (StrlSchV) the informed consent
forms including the patients’ consent for trial participation
and the application of irradiation will be archived for at
least 30 years after the end of the trial. The Study Center at
the Department of Radiation Oncology will be responsible
for archiving all relevant data.
Declaration of Helsinki and good clinical practice
The trial is conducted in accordance with the Declaration
of Helsinki (2008 Version of the Declaration of Helsinki,
adopted at the 59th WMA General Assembly, Seoul,
October 2008) as well as with the guidelines of Good
Clinical Practice (s. ICH-GCP: International Conference
on Harmonization - Good Clinical Practice; 01.05.1996) in
their current versions.
Ethics Committee and Bundesamt für Strahlenschutz
The study protocol, patient information and consent
are approved by the ethics committee of the university of
Heidelberg (S-165/2012). Furthermore, the trial is approved
by the Bundesamt für Strahlenschutz (Z5-22461/2-2009-
026/13).
Discussion
Currently, radical resection with/without adjuvant radiation
treatment is the most performed treatment in patients with
sacral chordoma. Hence, the evidence based only on
small retrospective series [11,14]. De Lany et al. published
data of 29 patients with chordomas of the mobile spine
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proton-/photon irradiation in a phase II trial. In this trial
no significant difference between R0 and R1/R2/biopsy
could be shown regarding local control [28]. According
to these results it can be asked whether an extended
surgery with high morbidity is still necessary. Japanese
retrospective data compared surgery only with carbon
ion therapy only and found out a 5-year local-recurrence
free survival rate of 62.5% for surgery and 100% for carbon
ion therapy [22]. Further retrospective data of 95 patients
after hypofractionated carbon ion treatment at NIRS
seems to indicate a new therapeutic option in patients
with sacral chordoma, which displays in contrast to the
surgery lower morbidity with very good local control [25].
Imai et al. reported about three patients with grade 3 skin
toxicity and two patients with grade 4 (73.6 GyE) [25]. A
decided evaluation of skin toxicity after carbon ion
treatment at NIRS showed grade 3 and 4 skin toxicity
only in patients which received doses ≥ 70 GyE in 16
fractions. It was indicated that severe skin reaction
may not develop if the prescribed dose is 64 GyE or less
like in our trial [29]. Furthermore, we limit the maximum
dose of the skin to 90-95% of the prescribed dose. Imai
et al. reported about one patient with rectal bleeding grade
1, but no patient received a colostomy or urinary diversion
after carbon ion treatment. 15 patients (16%) required
medication due to sciatic neuropathy after carbon ion
treatment. However, five of them received with 73.6 GyE a
much higher dose than in our trial. More than 80% of the
chordomas were localized above S2 [25]. Thus, the
expected toxicity after radical resection would have been a
complete urinary and bowel incontinence in at least
80% of the patients [20,21]. Furthermore chronic
neuropathic pain, wound complications and walking
difficulties are also possible side effects of sacrectomy
[30,31]. Against this background, the published side
effects after hypofractionated carbon ion therapy should
be evaluated.
Due to missing data for a hypofractionated carbon ion
therapy in raster scan technique, this trial will confirm the
historical data from Japan that were developed by using
passive beam application. In the Japanese trial patients re-
ceived a total dose of 52.8 to 73.6 GyE in 16 fractions.
Most of the patients received 70.4 GyE. In contrast to our
fractionation with up to 6 fractions per week (Monday-
Saturday), the patients in Japan received only four frac-
tions per week. Therefore, the total dose in our trial is lim-
ited to 64 GyE. Only patients with inoperable, residual or
recurrent tumor will be included in our trial. Patients with
resectable tumor are included only after refusal of surgery
treatment. Moreover, no data of hypofractionated proton
therapy in patients with sacral chordoma have been pub-
lished so far. However, these data are necessary to perform
a randomized prospective phase III study in the future.Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
MU, LE, ADJ, JD und KH have developed the study concept. MU, LE, KH and
JD wrote the study protocol and obtained ethics approval. LE was
responsible for statistical considerations. MU, ADJ, GH, JO, MBFR, JD and KH
will provide patient care. MU, LE, ADJ, GH, JO, MBFR, OJ, JD and KH will
implement the protocol and oversee collection of the data. All authors
contributed to and approved the final manuscript.
Acknowledgement
We acknowledge financial support by Deutsche Forschungsgemeinschaft
and Ruprecht-Karls-Universität Heidelberg within the funding programme
Open Access Publishing.
Author details
1Department of Radiation Oncology, University of Heidelberg, Im
Neuenheimer Feld 400, 69120 Heidelberg, Germany. 2Heidelberg Ion Therapy
Center (HIT), Im Neuenheimer Feld 450, 69120 Heidelberg, Germany.
3German Cancer Research Center (dkfz), Im Neuenheimer Feld 280, 69120
Heidelberg, Germany.
Received: 27 February 2014 Accepted: 24 April 2014
Published: 29 April 2014
References
1. Friedrich T, Scholz U, Elsasser T, Durante M, Scholz M: Calculation of the
biological effects of ion beams based on the microscopic spatial
damage distribution pattern. Int J Radiat Biol 2012, 88:103–107.
2. Kramer M, Weyrather WK, Scholz M: The increased biological effectiveness
of heavy charged particles: from radiobiology to treatment planning.
Technol Cancer Res Treat 2003, 2:427–436.
3. Scholz M, Kraft G: Track structure and the calculation of biological effects
of heavy charged particles. Adv Space Res 1996, 18:5–14.
4. Murakami M, Eguchi-Kasai K, Sato K, Minohara S, Yatagai F, Kanai T:
Differences in heavy-ion-induced DNA double-strand breaks in a
mouse DNA repair-deficient mutant cell line (SL3-147) before and after
chromatin proteolysis. J Radiat Res 1995, 36:258–264.
5. Heilmann J, Taucher-Scholz G, Haberer T, Scholz M, Kraft G: Measurement
of intracellular dna double-strand break induction and rejoining along
the track of carbon and neon particle beams in water. Int J Radiat Oncol
Biol Phys 1996, 34:599–608.
6. McMaster ML, Goldstein AM, Bromley CM, Ishibe N, Parry DM: Chordoma:
incidence and survival patterns in the United States, 1973–1995.
Cancer Causes Control 2001, 12:1–11.
7. Bjornsson J, Wold LE, Ebersold MJ, Laws ER: Chordoma of the mobile spine. A
clinicopathologic analysis of 40 patients. Cancer 1993, 71:735–740.
8. Rosenberg AE, Brown GA, Bhan AK, Lee JM: Chondroid chordoma–a
variant of chordoma. A morphologic and immunohistochemical study.
Am J Clin Pathol 1994, 101:36–41.
9. Chugh R, Tawbi H, Lucas DR, Biermann JS, Schuetze SM, Baker LH:
Chordoma: the nonsarcoma primary bone tumor. Oncologist 2007,
12:1344–1350.
10. Chen KW, Yang HL, Lu J, Liu JY, Chen XQ: Prognostic factors of sacral
chordoma after surgical therapy: a study of 36 patients. Spinal Cord 2010,
48:166–171.
11. Fuchs B, Dickey ID, Yaszemski MJ, Inwards CY, Sim FH: Operative
management of sacral chordoma. J Bone Joint Surg Am 2005, 87:2211–2216.
12. Osaka S, Kodoh O, Sugita H, Osaka E, Yoshida Y, Ryu J: Clinical significance
of a wide excision policy for sacrococcygeal chordoma. J Cancer Res Clin
Oncol 2006, 132:213–218.
13. York JE, Kaczaraj A, Abi-Said D, Fuller GN, Skibber JM, Janjan NA, York JE,
Kaczaraj A, Abi-Said D, Fuller GN, Skibber JM, Janjan NA, Gokaslan ZL: Sacral
chordoma: 40-year experience at a major cancer center. Neurosurgery
1999, 44:74–79. discussion 9–80.
14. Park L, Delaney TF, Liebsch NJ, Hornicek FJ, Goldberg S, Mankin H,
Rosenberg AE, Rosenthal DI, Suit HD: Sacral chordomas: Impact of
high-dose proton/photon-beam radiation therapy combined with or
without surgery for primary versus recurrent tumor. Int J Radiat Oncol Biol
Phys 2006, 65:1514–1521.
Uhl et al. Radiation Oncology 2014, 9:100 Page 8 of 8
http://www.ro-journal.com/content/9/1/10015. Munzenrider JE, Liebsch NJ: Proton therapy for tumors of the skull base.
Strahlenther Onkol 1999, 175(Suppl 2):57–63.
16. Hug EB, Loredo LN, Slater JD, DeVries A, Grove RI, Schaefer RA, Rosenberg AE,
Slater JM: Proton radiation therapy for chordomas and chondrosarcomas of
the skull base. J Neurosurg 1999, 91:432–439.
17. Ares C, Hug EB, Lomax AJ, Bolsi A, Timmermann B, Rutz HP, Schuller JC,
Pedroni E, Goitein G: Effectiveness and safety of spot scanning proton
radiation therapy for chordomas and chondrosarcomas of the skull base:
first long-term report. Int J Radiat Oncol Biol Phys 2009, 75:1111–1118.
18. Schulz-Ertner D, Karger CP, Feuerhake A, Nikoghosyan A, Combs SE, Jäkel O,
Edler L, Scholz M, Debus J: Effectiveness of carbon ion radiotherapy in the
treatment of skull-base chordomas. Int J Radiat Oncol Biol Phys 2007,
68:449–457.
19. Nikoghosyan AV, Karapanagiotou-Schenkel I, Munter MW, Jensen AD,
Combs SE, Debus J: Randomised trial of proton vs. carbon ion radiation
therapy in patients with chordoma of the skull base, clinical phase III
study HIT-1-Study. BMC Cancer 2010, 10:607.
20. Devin C, Chong PY, Holt GE, Feurer I, Gonzalez A, Merchant N, Schwartz HS:
Level-adjusted perioperative risk of sacral amputations. J Surg Oncol
2006, 94:203–211.
21. Cheng EY, Ozerdemoglu RA, Transfeldt EE, Thompson RC Jr: Lumbosacral
chordoma. Prognostic factors and treatment. Spine (Phila Pa 1976) 1999,
24:1639–1645.
22. Nishida Y, Kamada T, Imai R, Tsukushi S, Yamada Y, Sugiura H, Shido Y,
Wasa J, Ishiguro N: Clinical outcome of sacral chordoma with carbon ion
radiotherapy compared with surgery. Int J Radiat Oncol Biol Phys 2011,
79:110–116.
23. Imai R, Kamada T, Tsuji H, Sugawara S, Serizawa I, Tsujii H, Tatezaki S,
Working Group for Bone and Soft Tissue Sarcomas: Effect of carbon ion
radiotherapy for sacral chordoma: results of Phase I-II and Phase II
clinical trials. Int J Radiat Oncol Biol Phys 2010, 77:1470–1476.
24. Elsasser T, Kramer M, Scholz M: Accuracy of the local effect model for the
prediction of biologic effects of carbon ion beams in vitro and in vivo.
Int J Radiat Oncol Biol Phys 2008, 71:866–872.
25. Imai R, Kamada T, Sugahara S, Tsuji H, Tsujii H: Carbon ion radiotherapy for
sacral chordoma. Br J Radiol 2011, 84(Spec No 1):S48–S54.
26. Hall EJ: Intensity-modulated radiation therapy, protons, and the risk of
second cancers. Int J Radiat Oncol Biol Phys 2006, 65:1–7.
27. Blackwelder WC: “Proving the null hypothesis” in clinical trials. Control Clin
Trials 1982, 3:345–353.
28. DeLaney TF, Liebsch NJ, Pedlow FX, Adams J, Dean S, Yeap BY, McManus P,
Rosenberg AE, Nielsen GP, Harmon DC, Spiro IJ, Raskin KA, Suit HD, Yoon SS,
Hornicek FJ: Phase II study of high-dose photon/proton radiotherapy in the
management of spine sarcomas. Int J Radiat Oncol Biol Phys 2009, 74:732–739.
29. Yanagi T, Kamada T, Tsuji H, Imai R, Serizawa I, Tsujii H: Dose-volume
histogram and dose-surface histogram analysis for skin reactions to
carbon ion radiotherapy for bone and soft tissue sarcoma.
Radiother Oncol 2010, 95:60–65.
30. Davidge KM, Eskicioglu C, Lipa J, Ferguson P, Swallow CJ, Wright FC:
Qualitative assessment of patient experiences following sacrectomy.
J Surg Oncol 2010, 101:447–450.
31. Hulen CA, Temple HT, Fox WP, Sama AA, Green BA, Eismont FJ: Oncologic
and functional outcome following sacrectomy for sacral chordoma.
J Bone Joint Surg Am 2006, 88:1532–1539.
doi:10.1186/1748-717X-9-100
Cite this article as: Uhl et al.: Randomized phase II trial of
hypofractionated proton versus carbon ion radiation therapy in patients
with sacrococcygeal chordoma-the ISAC trial protocol. Radiation Oncology
2014 9:100.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
